{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-160146","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2024-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.120841+00:00","generated_at":"2026-06-01T04:36:33.255211+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"REGENXBIO appoints COO Curran Simpson as CEO; founder Kenneth Mills becomes Chairman","bullets":["Curran Simpson, former COO, appointed President and CEO effective July 1, 2024; also named to Board.","Co-founder Kenneth Mills steps down as CEO, becomes Chairman of the Board; advisor until June 2025.","Simpson's compensation: base salary $610k, bonus target 60%, equity grant $2.5M (75% options, 25% RSUs).","Daniel Tassé appointed Lead Independent Director, replacing Jerry Karabelas.","Company reiterates cash guidance: $380.5M as of March 31, 2024, funding ops into 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-160146","json":"https://secwatch.observer/filing/0001193125-24-160146.json","markdown":"https://secwatch.observer/filing/0001193125-24-160146.md","text":"https://secwatch.observer/filing/0001193125-24-160146.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/d718851d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T04:36:33.255211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03de9b4477","claim":"Daniel Tassé was appointed as Lead Independent Director at REGENXBIO Inc..","evidence_excerpt":"Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"},{"claim_id":"445c195975","claim":"Curran M. Simpson was appointed as President and Chief Executive Officer at REGENXBIO Inc..","evidence_excerpt":"the Company also announced that the Board appointed Curran M. Simpson as President and Chief Executive Officer, effective as of July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"87d7bec8bd","claim":"Curran M. Simpson was appointed as Class I director at REGENXBIO Inc..","evidence_excerpt":"In connection with his appointment, the Board appointed Mr. Simpson as a Class I director, effective July 1, 2024","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"},{"claim_id":"984e5d6f25","claim":"Jerry Karabelas departed as Lead Independent Director at REGENXBIO Inc..","evidence_excerpt":"Daniel Tassé was appointed as the Company's Lead Independent Director, succeeding Jerry Karabelas.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"succeeded"},{"label":"Role","value":"Lead Independent Director"}],"fact_type":"executive_change"},{"claim_id":"c891955d7e","claim":"Kenneth T. Mills was appointed as Chairman of the Board at REGENXBIO Inc..","evidence_excerpt":"accepted the resignation of Kenneth T. Mills from his position as President and Chief Executive Officer of the Company, effective July 1, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000119312524160146/0001193125-24-160146-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chairman of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}